Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Colorectal Cancer Patients
100%
Antitumor Activity
100%
MET Inhibitor
100%
Explant Model
100%
Cabozantinib
100%
VEGFR-2 Inhibitors
100%
Patient-derived Tumor Explants
100%
Tumor
50%
PIK3CA mutation
37%
Antitumor Effect
25%
Tumor Progression
25%
Vascular Endothelial Growth Factor
25%
Pathway Inhibitors
25%
Patient-derived Tumor Xenograft
25%
Growth Factor Pathway
25%
Antiangiogenic Therapy
25%
Colorectal Cancer Prevention
25%
Inhibitory Effect
12%
Tumorigenesis
12%
Tumor Growth
12%
Gene Expression
12%
Highly Sensitive
12%
Tumor Metastasis
12%
Clinical Trials
12%
Decreased Expression
12%
Major Contributor
12%
Akt Activation
12%
Prognostic Biomarker
12%
Angiogenesis Inhibitors
12%
Clinical Benefit
12%
Metastatic Colorectal Cancer (mCRC)
12%
Growth Factor Signaling Pathways
12%
Vascular Endothelial Growth Factor Signaling
12%
PIK3CA Gene
12%
Patients with Colorectal Cancer
12%
Treatment Resistance
12%
PI3K Pathway
12%
Chemotherapy Sensitivity
12%
Anticancer Drug Development
12%
MET Signaling Pathway
12%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Antitumor Activity
100%
Colorectal Carcinoma
100%
Cabozantinib
100%
Tumor Growth
37%
Vasculotropin
37%
Antiangiogenic Therapy
25%
Anticarcinogen
12%
Carcinogenesis
12%
Biological Marker
12%
Drug Development
12%
Clinical Trial
12%
Protein Kinase B
12%
Metastatic Colorectal Cancer
12%
Biochemistry, Genetics and Molecular Biology
Antineoplastic Activity
100%
Explant
100%
Cabozantinib
100%
Vascular Endothelial Growth Factor
37%
Tumor Progression
37%
Signal Transduction
25%
Carcinogenesis
12%
Upregulation
12%
Clinical Trial
12%
Anticancer
12%
Protein Kinase B
12%
Antiangiogenic Activity
12%
Drug Development
12%
Growth Factor Signaling
12%